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Abstract Daxx has been shown to play an essential in type I
interferon (IFN-K/L)-mediated suppression of B cell develop-
ment and apoptosis. Recently, we demonstrated that Tyk2 is
directly involved in IFN signaling for the induction and nuclear
translocation of Daxx, which may result in growth arrest and/or
apoptosis of B lymphocyte progenitors. To clarify the mecha-
nism of Daxx-mediated apoptosis signaling in B lymphocyte
progenitors, here we introduced an e⁄cient suicide switch in a
murine pro-B cell line, BAF3, by expressing FK506-binding
protein-fused Fas intracellular domain (FKBP-Fas) and Daxx.
It allows us to monitor Fas/Daxx-mediated signal by induction
of Fas dimerization with the dimerizer drug AP20187.
AP20187-mediated Fas dimerization induced not only apoptosis
but also Jun N-terminal kinase (JNK) activation. However,
AP20187 had no e¡ect on cells expressing either Fas or Daxx
only. Furthermore, expression of a JNK inhibitor, the JNK-
binding domain of JIP-1, resulted in resistance to AP20187-
mediated apoptosis in cells expressing FKBP-Fas and Daxx.
These results imply that our novel suicide switch system may
provide a powerful tool to delineate or identify the signaling
molecules for Daxx-mediated apoptotic machinery in B lympho-
cyte progenitors through JNK activation.
5 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Sequential rearrangements of immunoglobulin heavy and
light chain genes occur during B cell development, and the
defective or dangerous lymphocytes are eliminated by negative
selection [1]. Several cytokines and chemokines in the bone
marrow microenvironment deliver inhibitory or stimulatory
signals to B lymphocyte progenitors. For example, type I
interferons (IFN-K/L), which are produced by resident bone
marrow macrophages, can inhibit the interleukin (IL)-7-in-
duced growth and survival of B lymphocyte progenitors
[2,3]. Cross-linking of Fas, a member of the tumor necrosis^
nerve growth factor receptor superfamily, can induce apopto-
sis in B lymphocyte progenitors [4]. It is widely believed that
dysregulation or absence of these regulatory factors could
contribute to autoimmune and/or malignant diseases. Indeed,
mice carrying the lymphoproliferation (lpr) mutation have
defects in the Fas antigen gene. The lpr mice develop lympha-
denopathy and su¡er from a systemic lupus erythematosus-
like autoimmune disease [5].
Our experiments using Tyk2-de¢cient mice revealed that
Tyk2 is essential for the IFN-K/L-induced inhibition of colony
formation of B lymphocyte progenitors in response to IL-7
as well as the up-regulation and nuclear translocation of
Daxx [6]. Because Daxx plays crucial roles in IFN-K-in-
duced growth suppression of B lymphocyte progenitors [7],
it is very informative to analyze how Daxx is involved in
the growth arrest and/or apoptosis in early B cell develop-
ment.
Daxx was ¢rst identi¢ed as a Fas-binding protein by yeast
two-hybrid screening and was known as a pro-apoptotic pro-
tein that can enhance Fas-mediated apoptosis through Jun
N-terminal kinase (JNK) activation [8]. However, disruption
of Daxx in mice increased apoptosis during embryonic devel-
opment, suggesting that Daxx acts as an anti-apoptotic pro-
tein in the embryo [9]. Because of the diverse e¡ects of Daxx
between in vitro and in vivo experimental systems, the roles of
Daxx in apoptotic signals still remain unclear. While the in-
teraction between Daxx and Fas indicated the importance of
Daxx in the cytoplasm, nuclear localization of Daxx was ob-
served in various cell lines and interactions of Daxx with
several nuclear proteins such as the centromeric protein
CENP-C, Pax-3, Pax-5 and PML were reported [10^15].
Thus, Daxx is likely to play alternative roles in shuttling be-
tween the nucleus and the cytoplasm.
In this study, we established BAF3 cells expressing both
Daxx and a fusion protein composed of FK506-binding pro-
tein (FKBP) and membrane-anchored intracellular domain of
Fas, or each of them. A bivalent FKBP ligand could be a
trigger for apoptosis only when Daxx was overexpressed. Us-
ing these series of transfected BAF3 cells, we analyze and
discuss the roles of Daxx in Fas-mediated apoptotic signals
during B cell development.
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2. Material and methods
2.1. Reagents and antibodies
Mouse recombinant IFN-K was purchased from PBL Biomedical
Laboratories (Piscataway, NY, USA). A synthetic dimerizer,
AP20187, and an expression vector, pC4M-Fv2E, containing an
N-terminal myristoylation signal, two copies of FKBP, followed by
a C-terminal hemagglutinin (HA) tag were kindly provided by
ARIAD Gene Therapeutics (Cambridge, MA, USA). Expression vec-
tors, FLAG-tagged human Daxx in pcDNA3, JNK-binding domain
(JBD) of JIP-1 [16] in pcDNA3 and murine Fas cDNA [17] were
kindly provided by Dr. H. Ariga and Dr. T. Taira (Hokkaido Uni-
versity, Sapporo, Japan), Dr. R.J. Davis (University of Massachusetts
Medical School, Worcester, MA, USA) and Dr. S. Nagata (Osaka
University, Osaka, Japan), respectively. FKBP-Fas fusion was con-
structed by introducing the murine Fas cytoplasmic region into the
pC4M-Fv2E vector as described previously [18^21]. Brie£y, The cy-
toplasmic region (residues 166^306) of murine Fas [17] was subcloned
into the pCR vector (Invitrogen, San Diego, CA, USA) by polymerase
chain reaction (PCR) (primer sequences are available upon request),
and then inserted in pC4M-Fv2E to generate pC4M-Fv2E-Fas. Anti-
Daxx, anti-STAT1 and anti-HA antibody were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-FLAG M2 anti-
body was purchased from Sigma (St. Louis, MO, USA). JNK activa-
tion was determined by PhosphoPlus JNK antibody Kit (Cell Signal-
ing Technology, Beverly, MA, USA) according to the manufacturer’s
instructions. Z-VAD-fmk was purchased from Peptide Institute (Osa-
ka, Japan).
2.2. Cell culture, transfections, RT-PCR and cell viability assays
An IL-3-dependent murine pro-B cell line, BAF3, was maintained
in RPMI 1640 medium supplemented with 10% fetal calf serum and
10% conditioned medium from WEHI-3B cells as a source of IL-3
[22]. Stable transformants expressing either FKBP-Fas, Daxx, or both
of them were established as described previously [22]. Brie£y, BAF3
cells (1U107) were transfected with pcDNA3 plus pC4M-Fv2E-Fas,
pcDNA3-Daxx plus pC4M-Fv2E-Fas or pcDNA3-Daxx alone by
electroporation and selected in the above medium in the presence of
G418 (1 mg/ml). AP20187 stimulation was also performed in the
presence of IL-3. RT-PCR was performed using RT-PCR high
-Plus- Kit (Toyobo, Tokyo, Japan) (primer sequences are available
upon request). Cell viability was determined by Cell Counting Kit-8
(Wako Chemicals, Tokyo, Japan) according to the manufacturer’s
instructions.
2.3. Caspase assays and cell death assays
Caspase activity was determined by Apo-ONE Homogeneous Cas-
pase-3/7 Assay Kit (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. Annexin V assay was performed by An-
nexin-V-FLUOS Staining Kit (Roche Diagnostics, Mannheim, Ger-
many) according to the manufacturer’s instructions. TUNEL (TdT-
mediated dUTP nick end labeling) assay was performed by In Situ
Cell Death Detection Kit (Roche Diagnostics) according to the man-
ufacturer’s instructions.
2.4. Immunoprecipitation, immunoblotting and DNA fragmentation
The immunoprecipitation and Western blotting were performed as
described previously [23]. Cells were harvested and lysed in lysis bu¡er
(50 mM Tris^HCl, pH 7.4, 0.15 M NaCl, containing 1% NP-40, 1 WM
phenylmethylsulfonyl £uoride and 10 Wg/ml each of aprotinin, pepsta-
tin and leupeptin). The immunoprecipitates from cell lysates were
resolved on SDS^PAGE and transferred to Immobilon ¢lter (Milli-
pore, Bedford, MA, USA). The ¢lters were then immunoblotted with
each antibody. Immunoreactive proteins were visualized using an en-
hanced chemiluminescence detection system (Amersham Pharmacia
Biotech). DNA fragmentation assay was performed as described pre-
viously [24].
3. Results and discussion
3.1. Development of a conditional Fas/Daxx suicide switch
model in a pro-B cell line, BAF3
An IL-3-dependent murine pro-B cell line, BAF3 was em-
ployed to analyze mechanisms of growth arrest or apoptosis
via Daxx, because IFN-K inhibited their growth and up-regu-
lated their Daxx expression (Fig. 1A). To simplify the assay
system, we engineered a novel suicide switch model based on
the murine Fas receptor to trigger cell death in BAF3 cells.
We established three kinds of stably transfected BAF3 cells.
BAF/F2 and BAF/F3 expressed the HA-tagged fusion protein
composed of FKBP and membrane-anchored intracellular do-
main of Fas (FKBP-Fas), and BAF/D9 expressed FLAG-
tagged Daxx. BAF/FD7 and BAF/FD10 expressed both
FKBP-Fas and Daxx. Protein expression of the exogenous
FKBP-Fas and Daxx was con¢rmed with immunoblot analy-
sis using anti-HA or anti-FLAG antibodies (Fig. 1B). The
protein level of Daxx in transformants was about 10-fold
higher than endogenous Daxx protein by densitometric inten-
sity when compared using an anti-Daxx antibody (data not
shown).
In general, cross-linking of Fas results in the recruitment of
a death-inducing signaling complex, the activation of a pro-
teolytic cascade of caspases, and the induction of cell death by
apoptosis. Thus, aggregation of FKBP-Fas proteins by the
addition of a bivalent FKBP ligand, AP20187, was expected
to trigger the apoptotic death signals in BAF3 cells. However,
original BAF3 as well as BAF/F2 and BAF/F3 cells express-
ing FKBP-Fas did not die after the treatment with AP20187
(Fig. 1C). Overexpression of Daxx in BAF/D9 also had no
e¡ects on proliferation or survival. It is worth mentioning that
BAF/FD7 and BAF/FD10 expressing both FKBP-Fas and
Daxx strongly underwent cell death with the addition of
AP20187 as shown in Fig. 1C. Furthermore, aggregation
of FKBP-Fas on BAF/FD7 cells induced the association of
FKBP-Fas with Daxx (Fig. 1D). Therefore, Daxx directly
interacts with the intracellular domain of Fas and overexpres-
sion of Daxx enhances apoptotic signals mediated by Fas in a
murine pro-B cell line, BAF3.
3.2. AP20187-induced apoptosis in BAF/FD7 cells
Fas-induced apoptosis is known to be a rapid event that
occurs within a few hours. Some of the earliest detectable
events in the apoptotic pathway are loss of the cytoplasmic
polarization of plasma membrane phosphatidylserine and the
fragmentation of nuclear DNA. To determine the kinetics of
AP20187-induced cell death in BAF/FD7 cells, we treated
BAF/FD7 cells with 1 nM AP20187 and stained them with
annexin V at di¡erent times (Fig. 2A). Annexin V-positive
cells were clearly detectable within 3 h, and the percentage
of annexin V-positive cells continued to increase over time.
After 24 h of treatment with AP20187, 90% of the cells were
annexin V-positive. TUNEL staining showed a similar ki-
netics to that of annexin V (Fig. 2B). To con¢rm apoptosis,
the fragmentation of nuclear DNA in AP20187-untreated or
-treated BAF/FD7 cells was analyzed. As shown in Fig. 2C,
after 12 h of treatment with AP20187, BAF/FD7 cells clearly
showed the degradation of chromosomal DNA. Therefore, a
dimerizer of FKBP-Fas, AP20187, e¡ectively induces apopto-
sis in BAF/FD7 cells.
3.3. Caspase activation and the enhanced JNK activation by
AP20187 in BAF/FD7 cells
To delineate the molecular mechanisms in AP20187-in-
duced apoptosis of murine B lymphocyte progenitors,
AP20187-induced caspase activation in BAF/FD7 cells was
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analyzed. As shown in Fig. 3A, the caspase-3/7 activity in-
creased after 3 h with AP20187 in BAF/FD7 but not BAF/
F2 cells. We then examined whether the activation of the
caspase cascade is related to AP20187-induced cell death. As
shown in Fig. 3A, Z-VAD-fmk, a broad caspase inhibitor,
inhibited AP20187-induced cell death in BAF/FD7 cells. Ad-
dition of Z-VAD-fmk also inhibited AP20187-induced apo-
ptosis monitored by annexin V and TUNEL staining (data
not shown). Therefore, caspase activation is necessary for
AP20187-induced apoptosis in BAF/FD7 cells.
Fig. 1. Development of a conditional Fas/Daxx suicide switch for use in BAF3 cells. A: E¡ects of IFN-K on the growth and Daxx induction
in BAF3 cells. IFN-K inhibits the proliferation of the mouse IL-3-dependent pro-B cell line, BAF3 cells. BAF3 cells were cultured with IFN-K
at the indicated concentration for 24 h. Cell viability was determined by Cell Counting Kit-8. Western blot analysis of Daxx and STAT1 pro-
tein levels in total extracts of BAF3 cells treated without or with IFN-K (50 U/ml) for 16 h. B: Expression of FKBP-Fas and/or Daxx proteins
in each transformant as indicated. The immunoprecipitates with anti-HA antibody (upper) and total extracts (lower) were examined by Western
blot analysis using anti-HA or anti-FLAG antibodies as indicated. C: Each transformant was treated with the indicated concentrations of
AP20187 for 24 h. Cell viability was determined by Cell Counting Kit-8 as described in Section 2. The results are presented from three inde-
pendent experiments, and the error bars represent the standard deviations. D: AP20187-dependent association of FKBP-Fas with Daxx in
BAF/FD7 cells. BAF/FD7 and BAF/D9 cells (2U107) were treated without or with AP20187 (10 nM) for 30 min. Cell lysates were then immu-
noprecipitated and immunoblotted with anti-FLAG (upper) or anti-HA (middle) antibodies as indicated. Total extracts (20 Wg) were examined
by Western blot analysis using anti-FLAG antibody (lower).
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Previous studies demonstrated that Fas/Daxx also activates
the JNK pathway [8]. Recently, Daxx has also been shown to
physically interact with the cytoplasmic domain of the type II
transforming growth factor (TGF)-L receptor and mediate
TGF-L-induced apoptosis and activation of JNK [25]. To as-
sess the possibility whether AP20187 induces JNK activation
in BAF/FD7 cells, the kinetics of AP20187-induced JNK ac-
tivation in BAF/FD7 cells was analyzed. JNK activation was
monitored by immunoblotting using an antibody directed
against phospho-JNK Thr183/Tyr185. As shown in Fig. 3B,
upon AP20187 stimulation, strong sustained phosphorylation
of JNK was induced in BAF/FD7 cells, compared with that of
BAF/F2 cells. We next examined whether the sustained acti-
vation of JNK is critical in AP20187-mediated apoptosis in
BAF/FD7 cells or not. For this purpose, we expressed JBD
from JIP-1 in BAF/FD7 cells, which is known as a potent
JNK inhibitor. As shown in Fig. 3C, each established BAF/
FD7 clone expressing JBD showed resistance to AP20187-in-
duced apoptosis. Therefore, JNK activation by AP20187 is
also essential in the apoptotic signals in BAF/FD7 cells.
3.4. Conclusions
We have here shown the development of a conditional Fas/
Daxx suicide switch for use in murine B lymphocyte progen-
itors. We introduced an e⁄cient suicide switch in a murine
pro-B cell line, BAF3, by expressing Daxx and FKBP-Fas.
Using this cell line, we succeeded in monitoring Fas/Daxx-
mediated apoptotic signals by induction of Fas dimerization
with the dimerizer drug, AP20187. AP20187-mediated Fas di-
merization induced not only caspase activation but also JNK
activation. Furthermore, expression of a JNK inhibitor re-
sulted in resistance to AP20187-mediated apoptosis in BAF3
cells expressing FKBP-Fas and Daxx. These results demon-
strate that our novel suicide switch system in B lymphocyte
progenitors is dependent on Fas and its enhancer, Daxx.
Daxx was reported to be involved in the Fas- and TGF-L-
mediated apoptotic signaling pathway [8,25]. Daxx was orig-
inally cloned as a Fas-associated protein and binds speci¢cally
to the death domain of Fas, although Daxx itself lacks a
death domain [8]. There are two independent signaling path-
ways downstream of Fas, involving the adapter protein Fas-
associated death domain (FADD) and Daxx [5,8]. The acti-
vation of FADD induces a protease cascade [26], while that of
Daxx enhances JNK activation, leading to apoptosis [8].
Overexpression of Daxx enhances Fas-induced apoptosis
[8,13], and the targeted disruption of the Daxx gene in mice
results in embryonic lethality [9]. Daxx is also involved in the
coupling of type II TGF-L receptor signaling with compo-
nents of the apoptotic machinery [25]. TGF-L induces apopto-
sis in primary and cultured lymphocytes [27]. Daxx associates
with the cytoplasmic domain of the type II TGF-L receptor
and transduces apoptotic signals by TGF-L [25].
Recently, Daxx was also reported to be essential for IFN-
induced suppression of B cell development [7]. IFN-K enhan-
ces Daxx expression, with concomitant increases in Daxx pro-
tein levels and nuclear body translocation. Moreover, Daxx
antisense oligonucleotides rescue IFN-K-treated pro-B cells
from growth arrest and apoptosis. We also demonstrated
that Tyk2 is essential for the transduction of IFN-K-induced
suppression of B cell development through the activation of
some signaling molecules other than STAT1, followed by the
up-regulation and nuclear translocation of Daxx [6]. The ap-
optotic signaling pathway downstream of Daxx still remains
unknown. One candidate of Daxx targets is a JNK signaling
pathway. Alternatively, the localization of Daxx is also im-
portant, since the localization of Daxx in either the cytoplas-
mic or nuclear compartment was reported to be dependent
upon the cell type and/or its functional status [28].
The present paper describes the establishment of an IL-3-
dependent pro-B cell line, BAF/FD7, which has an e⁄cient
Fig. 2. AP20187-induced apoptosis in BAF/FD7 cells. A: BAF/FD7 cells (2U105) were treated with AP20187 (1 nM) for the indicated time
and stained with Annexin-V-FLUOS Staining Kit as described in Section 2. B: BAF/FD7 cells (5U105) were treated with AP20187 (1 nM) for
the indicated time and stained with TUNEL using In Situ Cell Death Detection Kit as described in Section 2. C: BAF/FD7 cells (1U107) were
treated without or with AP20187 (1 nM) for 12 h. Total DNA was extracted from cells and electrophoresed on a 1% agarose gel in the pres-
ence of 1 Wg/ml ethidium bromide.
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Fig. 3. Caspase activation and the enhanced JNK activation by AP20187 in BAF/FD7 cells. A: Caspase activation by AP20187 and e¡ect of
caspase inhibitor on AP20187-induced cell death in BAF/FD7 cells. BAF/F2 or BAF/FD7 cells (2U104) were treated with AP20187 (1 nM) for
the indicated time and the caspase activity was determined by Apo-ONE Homogeneous Caspase-3/7 Assay Kit as described in Section 2. BAF/
FD7 cells (2U104) were treated without or with AP20187 (1 nM) in the absence or presence of the caspase inhibitor Z-VAD-fmk (100 nM) for
24 h. Cell viability was determined by Cell Counting Kit-8 as described in Section 2. The results are presented from three independent experi-
ments, and the error bars represent the standard deviations. B: JNK activation by AP20187 in BAF/FD7 cells. BAF/F2 or BAF/FD7 cells
(2U106) were treated with dimethyl sulfoxide or AP20187 (1 nM) for the indicated time and lysed, and immunoblotted with an anti-phospho
JNK antibody (upper panel) or an anti-JNK antibody (lower panel). C: E¡ect of JBD expression on AP20187-induced cell death in BAF/FD7
cells. JBD and G3PDH transcripts were analyzed by RT-PCR in each transformant as indicated. Cells (2U104) were treated with the indicated
concentrations of AP20187. 24 h after treatment, cell viability was determined by Cell Counting Kit-8 as described in Section 2. The results are
presented from three independent experiments, and the error bars represent the standard deviations.
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suicide switch dependent on Fas/Daxx. This cell line is useful
to delineate the apoptotic signaling pathway downstream of
Daxx through the JNK signaling pathway and is also a
powerful tool to identify novel molecules involved in Daxx-
mediated apoptosis in B lymphocyte progenitors.
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